GlassScriptPhysician profile
Singh A Boun
NPI 1801855028
$46,470.83
in general payments reported to CMS, 2019-2025
63 companies · $6,599 in 2025
The $6,599 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,230 · 2020: $5,085 · 2021: $7,048 · 2022: $7,440 · 2023: $6,946 · 2024: $6,122 · 2025: $6,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,667.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,889.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $3,554.14 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $3,173.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Amarin Pharma, INC. | $2,807.23 | 2019-2023 | |
| Abbvie INC. | $2,602.52 | 2019-2025 | Linzess, Vraylar, Viberzi |
| Pfizer INC. | $2,149.09 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,580.49 | 2019-2025 | Jardiance |
| Ibsa Pharma INC. | $1,572.43 | 2021-2025 | Tirosint, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,563.16 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Horizon Therapeutics Plc | $1,551.85 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,454.37 | 2019-2025 | |
| Lilly USA, LLC | $1,231.26 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Ironwood Pharmaceuticals, INC | $1,209.19 | 2019-2025 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $1,177.40 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,012.13 | 2019-2024 | Xarelto |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $944.70 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Ardelyx, INC. | $884.39 | 2023-2025 | Ibsrela |
| Esperion Therapeutics, INC. | $865.14 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $864.46 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $837.05 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $732.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Eisai INC. | $654.19 | 2020-2025 | |
| Allergan, INC. | $479.77 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $412.16 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $382.63 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $332.66 | 2020-2021 | |
| Almatica Pharma LLC | $327.68 | 2021-2025 | Loreev Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $315.33 | 2022 | |
| Radius Health, INC. | $264.62 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $259.61 | 2024 | |
| Redhill Biopharma INC. | $251.67 | 2022 | |
| Sun Pharmaceutical Industries INC. | $245.97 | 2021-2023 | Xelpros, Cequa |
| Exact Sciences Corporation | $238.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $232.48 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $220.61 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $206.28 | 2020-2022 | |
| Abbott Laboratories | $180.80 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.84 | 2023-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $165.37 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Genzyme Corporation | $162.18 | 2023-2025 | |
| Ascend Therapeutics US, LLC | $160.72 | 2020-2023 | |
| Corium, LLC | $139.23 | 2022-2023 | Adlarity |
| Regeneron Healthcare Solutions, INC. | $107.96 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $82.56 | 2024-2025 | Zenpep, Vowst |
| Kyowa Kirin, INC. | $77.71 | 2024 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $77.40 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $72.54 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $64.03 | 2024-2025 | Rexulti |
| Biogen, INC. | $58.21 | 2020-2021 | |
| Dexcom, INC. | $55.13 | 2023-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $48.52 | 2022 | |
| Eyevance Pharmaceuticals LLC | $44.55 | 2021 | |
| Gilead Sciences, INC. | $42.03 | 2019-2022 | |
| Vivus LLC | $39.03 | 2023-2024 | Pancreaze |
| Idorsia Pharmaceuticals US INC | $38.60 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $35.48 | 2020-2024 | |
| Medicure Pharma INC. | $31.57 | 2021 | |
| Vertiflex, INC. | $29.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.06 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $20.22 | 2025 | |
| Lundbeck LLC | $18.33 | 2024 | Rexulti |
| Cranial Technologies, INC | $16.36 | 2023 | Doc Band |
| Genentech USA, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Singh Boun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.